Skip to main content
. 2014 Nov 19;69(6):707–711. doi: 10.1038/ejcn.2014.251

Table 2. Effect of Vitamin D3 supplementation on obese type 2 diabetic subjects.

Variable Vitamin D-group
Placebo group
  Baseline Phase 1 (6000 IU/day) Phase 2 (3000 IU/day) Baseline Phase 1 Phase 2
Weight (kg) 95.5±17.7 95.0±18.1 94.7±18.2 94.2±23.3 95.0±23.4 95.2±23.4
Systolic blood pressure (mm Hg) 128±20 133±16 133±12 131±18 132±19 133±19
Diastolic blood pressure (mm Hg) 70±12 74±9 73±9 73±9 73±10 73.±9
S-25(OH) vitamin D (nmol/l) 28.5±9.2 77.2±30.1a 62.3±20.8a,b 30.5±11.3 28.8±12.9 25.4±11.8a
P-calcium (mmol/l) 2.31±0.08 2.31±0.89 2.30±0.89 2.35±0.10 2.32±0.11 2.29±0.10a
P-phosporous (mmol/l) 1.16±0.18 1.21±0.16 1.17±0.13 1.17±.14 1.20±0.21 1.10±0.18
P-parathyroid hormone(pmol/l) 5.9±2.4 5.0±2.5 4.5±1.8a 5.4±2.3 5.4±2.4 5.5±2.4
P-alkaline phosphotase (IU/l) 73.9±17.7 69.4±16.7 69.5±16.0 81.2±22.6 76.3±22.5 77.9±24.6
P-fasting glucose (mmol/l) 9.3±2.8 9.8±3.1 9.5±2.9 8.9±3.2 9.2±3.4 9.7±3.7
B-HbA1c (%) 8.2±1.3 8.2±1.4 8.0±1.5 8.3±1.8 8.4±1.8 8.3±1.9
P-C-peptide (nmol/l) 1.2±0.5 1.3±0.5 1.2±0.5 1.0±0.4 1.0±0.4 1.0±0.4
P-CRP (mg/l) 7.4±7.6 7.8±10.8 8.0±9.5 8.0±9.2 9.5±10.4 10.0±13.0
P-creatinin (mmol/l) 55.5±14.3 57.1±20.3 54.3±13.1 54.0 ±16.1 51.6±13.6 53.0±15.2
P- cholesterol (mmol/l) 4.3±1.0 4.2±0.9 4.3±1.0 4.1±0.9 4.0±0.8 4.3±1.3
P-HDL-cholesterol (mmol/L) 1.1±0.2 1.1±0.2 1.1±0.2 1.1±0.3 1.1±0.2 1.1±0.2
P-LDL-cholesterol (mmol/l) 2.7±0.8 2.5±0.8 2.6±0.9 2.4±0.8 2.4±0.8 2.5±1.0
P-Triglyceride (mmol/l) 1.6±1.1 1.7±1.1 1.6±0.8 1.8±1.1 1.8±1.4 1.9±1.8

Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Mean±s.d. (all such values).

a

Denotes significance compared with baseline.

b

Denotes significance compared with phase 1 (P<0.05). These comparisons were only performed when the group comparison P-value was <0.05.